bioRxivGeneticsPreprint
Structural semantic evolutionary distance (SSED) unifies the selection of cancer driver genes across macroevolution and tumorigenesis.
Hongchen JiiD, Q Y ZhangiD, Jianwei Wu, Fei Tian, Xiangxu WangiD, Xiao Chai, Jiawei Chang, Mengdi Zheng, X. M. Li, Hong-Mei ZhangiD
Abstract
The non-random, site-specific enrichment of somatic mutations in cancer driver genes (CDGs) suggests their emergence is governed by underlying evolutionary constraints. However, quantitative methods to define these constraints and their underlying principles remain underexplored. To address this, we introduce the Structural Semantic Evolutionary Distance (SSED), a metric leveraging the pretrained ESM-3 protein language model to quantify evolutionary divergence within a unified structural semantic space. Our analysis demonstrates that CDGs are subject to persistent structural semantic constraints across species, tolerating a significantly narrower range of structural semantic changes during evolution compared to non-CDGs. Crucially, clinically observed oncogenic mutations follow this same principle, favoring minimal structural perturbation as shaped by long-term gene evolution. Such mutations maintain core protein function while conferring a capacity for immune evasion, thereby driving clonal expansion. Guided by this "evolutionary constraint" framework, we successfully predicted and experimentally validated a previously uncharacterized oncogenic mutation, KRAS R135L, in bronchial epithelial cells. Furthermore, clinical cohort analysis demonstrated that SSED acts as an independent predictor of response to immune checkpoint blockade, offering information orthogonal to tumor mutational burden (TMB). This study unifies the evolutionary principles governing CDGs across macroevolutionary and microevolutionary (tumorigenesis) timescales, elucidates the balance between structural adaptability, functional conservation, and immune pressure, and identifies a novel predictive biomarker for cancer immunotherapy.
- organism: human
- assay: proteomics
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- research focus: benchmarking
- research focus: database / resource
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immune evasion impacts the selective landscape of driver genes during tumorigenesis
Lucie E. Gourmet, Andrea Sottoriva, … Luis Zapata·bioRxiv·Jun 20, 2022
- Protein structural context of cancer mutations reveals molecular mechanisms and identifies novel candidate driver genes
Diego Chillón Pino, Mihaly Badonyi, … Joseph A. Marsh·bioRxiv·Mar 21, 2024
- Mutational likeliness and entropy help to identify driver mutations and their functional role in cancer
Giorgio Mattiuz, Salvatore Di Giorgio, … Silvestro G Conticello·bioRxiv·Jun 26, 2018
- Computational structure prediction methods enable the systematic identification of oncogenic mutations
X. Fu, C. Reglero, … R. Rabadan·bioRxiv·Nov 18, 2022
- Bayesian Inference Of Cancer Driver Genes Using Signatures Of Positive Selection
Luis Zapata, Hana Susak, … Stephan Ossowski·bioRxiv·Apr 13, 2017
- The theory of massively repeated evolution and full identifications of Cancer Driving Nucleotides (CDNs)
Lingjie Zhang, Tong Deng, … Chung‐I Wu·bioRxiv·May 29, 2024